Detailed price information for Madrigal Pharmaceuticals Inc (MDGL-Q) from The Globe and Mail including charting and trades.

Proceeds to primarily support MASH pipeline expansion and to refinance existing senior credit facility <li /> $350 million initial term ...

Madrigal Pharmaceuticals MDGL shares soared 10.9% on Wednesday. The uptrend was observed after the U.S. Patent and Trademark ...

Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL) saw its stock climb 6.1% following the announcement that the U.S. Patent and Trademark Office has issued a Notice of Allowance for its MASH treatment, ...

Madrigal Pharmaceuticals earned an important regulatory approval this year. However, the biotech faces risks, including the need for a post-marketing study. While the new medicine has good ...

Earlier this year, Madrigal Pharmaceuticals (NASDAQ: MDGL) launched its first product, Rezdiffra. It wasn't just an important breakthrough for the mid-cap biotech; Rezdiffra became the first ...

CONSHOHOCKEN, Pa., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for nonalcoholic ...

Madrigal Pharmaceuticals sought to secure $500 million through a public offering comprising 1.25 million common shares priced at $151.69 each and pre-funded warrants for an additional 2.05 million ...

Madrigal Pharmaceuticals, Inc. stock has enjoyed peaks and troughs as it has pursued its path to the approval of NASH drug Rezdiffra. The company's stock was buoyant yesterday, enjoying a 15% gain ...

Patients with MASH/NASH treated with Rezdiffra experienced clinically meaningful and statistically significant improvements in emotional well-being and health distress Study results underscore the ...

Madrigal Pharmaceuticals' (NASDAQ: MDGL) shares are down by 27% over the past year, while the S&P 500 is up by 26%. However, this poor performance hardly reflects the progress the biotech has made.

Madrigal Pharmaceuticals' (MDGL-0.87%) shares are down by 27% over the past year, while the S&P 500 is up by 26%. However, this poor performance hardly reflects the progress the biotech has made.